Lupin Executive Says Indian Firm Seeks U.S. Buys Up To $500 Million
This article was originally published in PharmAsia News
Lupin is looking for acquisitions in the U.S., both for drug makers and for brands to buy, says Vineeta Gupta, the Indian company’s group president.
You may also be interested in...
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.